Drug
Sar442257
Sar442257: highest development phase Phase 1, developed by Sanofi. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1
- Developer
- Sanofi
Trials
| Drug | Phase | Indication |
|---|---|---|
| SAR442257 NCT04401020 | Phase 1 | Neoplasm Malignant |
Latest
No recent events.
Follow Sar442257 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.